论文部分内容阅读
目的:研究草酸铂(OXA,艾恒)与5蛳氟尿嘧啶联合化疗治疗中晚期大肠癌的近期疗效和毒副作用。方法:将56例中晚期大肠癌患者随机分为艾恒、5蛳氟尿嘧啶化疗组(OF组)和顺铂、5蛳氟尿嘧啶联合化疗组(PF组)。OF组:艾恒150 mg第1天,5蛳氟尿嘧啶750 mg第1天~第5天。PF组:顺铂40 mg第1天~第3天,5蛳氟尿嘧啶750 mg第1天~第5天。结果:OF组有效率为42.9 %(12/28),PF组为39.2 %(11/28),两组间差异无显著性(P>0.05)。OF组和PF组的中位总生存时间分别为8个月和7个月(P>0.05),OF组的Ⅲ度~ Ⅳ度恶心呕吐发生率为10.7 %(3/28),明显低于PF组的35.7 %(10/28),两组差异有显著性(P<0.05)。结论:艾恒、5蛳氟尿嘧啶联合化疗治疗中晚期大肠癌的近期疗效好,且毒副作用低,值得推广。
Objective: To study the short-term curative effect and toxicity of oxaliplatin (OXA, Aiheng) combined with 5-fluorouracil in the treatment of advanced colorectal cancer. Methods: Fifty-six patients with advanced and advanced colorectal cancer were randomly divided into Aiheng group, OF group, OFT group, and cisplatin group and PFU group of 5FU group. OF group: 150 mg aiheng day 1, 750 mg fluorouracil 750 mg day 1 to day 5 PF group: Cisplatin 40 mg Day 1 - Day 3, 5 蛳 Fluorouracil 750 mg Day 1 - Day 5. Results: The effective rate was 42.9% (12/28) in OF group and 39.2% (11/28) in PF group. There was no significant difference between the two groups (P> 0.05). The median overall survival time in OF and PF groups was 8 months and 7 months (P> 0.05). The incidence of grade III-IV nausea and vomiting in OF group was 10.7% (3/28), significantly lower than PF group 35.7% (10/28), the difference between the two groups was significant (P <0.05). Conclusions: Aiheng and 5-fluorouracil combined with chemotherapy have good short-term curative effect in treating advanced and advanced colorectal cancer with low toxic and side effects and should be promoted.